7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Inclusion Criteria: * Part I (closed to accrual as of 6/8/2007) * Histologically confirmed solid tumor that is metastatic or unresectable for which standard curative measures do not exist or are no longer effective, including the following: * Gastrointestinal tract cancer * Lung cancer * Breast cancer * Ovarian cancer * Endometrial cancer * Cervical cancer * Prostate cancer * Head and neck cancer * Patients with or without measurable or evaluable disease allowed * Measurable disease, defined as ≥ 1 unidimensionally measurable lesion \> 20 mm by conventional techniques or ≥ 10 mm with spiral CT scan * Tumor markers allowed for evaluable disease * Positive bone scan, osteoblastic metastases, and pleural or peritoneal effusions are not considered measurable or evaluable disease * No known brain metastases * Part II * Histologically confirmed (either primary or the recurrent site) locally recurrent or metastatic breast cancer not amendable to surgery * Measurable disease * For skin lesions, documentation by color photography and estimation of lesion size with a ruler are required * Must have undergone prior therapy with an anthracycline and a taxane either in the adjuvant or metastatic setting * CNS metastasis allowed provided stable disease (i.e., no evidence of local progression) ≥ 3 months after local therapy * Hormone receptor status: * Estrogen receptor negative * Progesterone receptor n…